Genentech Submits New Drug Application to FDA for Vismodegib for Rare Form of Advanced Skin Cancer Full Text
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced that the company has submitted a New Drug Application for vismodegib to the U.S. Food and Drug Administration (FDA) for the treatment of people with advanced basal cell carcinoma (BCC) for whom surgery is considered inappropriate. Vismodegib is an investigational, oral, targeted medicine designed to selectively inhibit signaling in the Hedgehog pathway, which is implicated in more than 90 percent of BCC cases. BCC is the most common type of skin cancer, which is generally considered curable by surgery. However, when it advances, BCC can cause disfiguring and debilitating effects and can ultimately be life–threatening.